Regulatory

Regulatory

Navamedic ASA: Commencement of the subscription period for the rights issue

Navamedic ASA: Approval and publication of prospectus

Navamedic ASA: Updated key information relating to the rights issue

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries.

Navamedic ASA: Invitation to 2025 2nd quarter presentation